

# OBLITERIDE 2021 MEDIA FACTS



## ABOUT OBLITERIDE

- Fred Hutch Obliteride is a community event that unites people of all ages, abilities, and fitness levels to have fun, honor loved ones, and raise critical funding for cancer research.
- Each August, Obliteriders ride, walk, or run and raise millions of dollars to fuel our fearless scientists.
- Due to the continuing pandemic, Obliteride's 2021 season will be virtual.
- Instead of an in-person weekend, participants are invited to pick any activity they love and complete it on or before August 14, 2021.
- Participants will be supported with online challenges, teams, happy hours, and events.
- Obliteride has a flat \$35 registration fee and no fundraising minimums. This year, Fred Hutch invites everyone to make the event their own and fundraise what they can.
- 100% of participant-raised dollars will support cancer research.
- Over its first eight years, Fred Hutch Obliteride has funded more than \$32 million in breakthrough research on cancer, COVID, HIV, and other diseases.
- Obliteriders know that researchers can't cure cancer alone — it takes everyone to fuel the bold research today that will help our loved ones tomorrow.

## OBLITERIDE BY THE NUMBERS

- In 2020, more than 3,000 people from all 50 U.S. states, 17 countries, and all 7 continents joined Fred Hutch Obliteride.
- Participants rode bikes, walked, ran, kayaked, hiked, did puzzles and more to fuel cancer research.
- 2021 marks Obliteride's ninth year.
- More than 17,000 people have joined Obliteride since 2013.
- More than 73,000 donors have supported Obliteride since 2013.
- Fred Hutch Obliteride has raised more than \$32 million for research since 2013.

## ABOUT FRED HUTCH

- Fred Hutch researchers are pushing the limits of human knowledge and tackling disease from every angle. Through fearless science, they are leading the way to a world where no person has to fear cancer.
- More than 3,000 Fred Hutch faculty work to eliminate cancer, HIV, and other diseases.
- Fred Hutch relies on private donations like those raised through Obliteride to launch new studies faster, bring breakthrough ideas to patients more quickly, and fuel the development of lifesaving therapies.

